Brief: Finch Therapeutics Group Inc - Matthew P. Blischak Appointed As Chief Executive Officer Effective May 16, 2023
25/04/2023 22:11
Finch Therapeutics Group Inc FNCH.O :
* FINCH THERAPEUTICS GROUP INC - MATTHEW P. BLISCHAK
APPOINTED AS
CHIEF EXECUTIVE OFFICER EFFECTIVE MAY 16, 2023
* FINCH THERAPEUTICS GROUP INC - LANCE THIBAULT, TO SERVE AS
CHIEF
FINANCIAL OFFICER EFFECTIVE MAY 16, 2023
* FINCH THERAPEUTICS GROUP INC - MARC BLAUSTEIN TO COMPLETE
HIS
TIME AS PRINCIPAL FINANCIAL OFFICER EFFECTIVE MAY 15
* FINCH THERAPEUTICS GROUP INC - BLAUSTEIN IS EXPECTED TO
REMAIN
ENGAGED WITH COMPANY AS A STRATEGIC ADVISOR
Source text for Eikon: ID:nGNX6xvRdR
Further company coverage: FNCH.O
Recent news on Finch Therapeutics
See all newsFinch wins US jury trial against Ferring over fecal-transplant patents
Brief: Finch Therapeutics Group Received A Notice From Nasdaq Acknowledging Fact That Co Does Not Meet Requirements Of Rules On April 2
Brief: Finch Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq’s Listing Rule 5450(A)(1)
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp